EUROBIO-SCIENTIFIC (ALERS.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALERS - FR0013240934 - Common Stock
24.3 EUR
+0.1 (+0.41%)
We assign a fundamental rating of 6 out of 10 to ALERS. ALERS was compared to 83 industry peers in the Biotechnology industry. ALERS has an excellent financial health rating, but there are some minor concerns on its profitability. ALERS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ALERS had positive earnings in the past year.
In the past year ALERS had a positive cash flow from operations.
In the past 5 years ALERS has always been profitable.
Each year in the past 5 years ALERS had a positive operating cash flow.
1.2 Ratios
ALERS's Return On Assets of 0.91% is fine compared to the rest of the industry. ALERS outperforms 72.29% of its industry peers.
ALERS has a better Return On Equity (1.30%) than 75.90% of its industry peers.
The Return On Invested Capital of ALERS (4.00%) is better than 72.29% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ALERS is significantly below the industry average of 12.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| ROIC | 4% |
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
1.3 Margins
Looking at the Profit Margin, with a value of 1.46%, ALERS is in the better half of the industry, outperforming 73.49% of the companies in the same industry.
In the last couple of years the Profit Margin of ALERS has declined.
Looking at the Operating Margin, with a value of 7.62%, ALERS is in the better half of the industry, outperforming 72.29% of the companies in the same industry.
ALERS's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 46.95%, ALERS perfoms like the industry average, outperforming 43.37% of the companies in the same industry.
In the last couple of years the Gross Margin of ALERS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.62% | ||
| PM (TTM) | 1.46% | ||
| GM | 46.95% |
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALERS is destroying value.
The number of shares outstanding for ALERS remains at a similar level compared to 1 year ago.
ALERS has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ALERS has been reduced compared to a year ago.
2.2 Solvency
ALERS has an Altman-Z score of 3.74. This indicates that ALERS is financially healthy and has little risk of bankruptcy at the moment.
ALERS's Altman-Z score of 3.74 is fine compared to the rest of the industry. ALERS outperforms 77.11% of its industry peers.
ALERS has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
ALERS has a better Debt to FCF ratio (1.48) than 86.75% of its industry peers.
ALERS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ALERS has a better Debt to Equity ratio (0.07) than 68.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 3.74 |
ROIC/WACC0.57
WACC7.06%
2.3 Liquidity
A Current Ratio of 1.79 indicates that ALERS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.79, ALERS is in line with its industry, outperforming 42.17% of the companies in the same industry.
A Quick Ratio of 1.25 indicates that ALERS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.25, ALERS is not doing good in the industry: 63.86% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.25 |
3. Growth
3.1 Past
ALERS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -63.15%.
ALERS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.82% yearly.
ALERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.47%.
ALERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.21% yearly.
EPS 1Y (TTM)-63.15%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
3.2 Future
The Earnings Per Share is expected to grow by 13.32% on average over the next years. This is quite good.
ALERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 105.65 indicates a quite expensive valuation of ALERS.
Based on the Price/Earnings ratio, ALERS is valued a bit cheaper than the industry average as 72.29% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ALERS to the average of the S&P500 Index (26.59), we can say ALERS is valued expensively.
A Price/Forward Earnings ratio of 20.88 indicates a rather expensive valuation of ALERS.
83.13% of the companies in the same industry are more expensive than ALERS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, ALERS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 105.65 | ||
| Fwd PE | 20.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALERS indicates a rather cheap valuation: ALERS is cheaper than 89.16% of the companies listed in the same industry.
80.72% of the companies in the same industry are more expensive than ALERS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.01 | ||
| EV/EBITDA | 7.77 |
4.3 Compensation for Growth
ALERS has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ALERS's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)N/A
PEG (5Y)15.5
EPS Next 2Y13.32%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ALERS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALERS (12/10/2025, 7:00:00 PM)
24.3
+0.1 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.81%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap249.07M
Revenue(TTM)162.09M
Net Income(TTM)2.36M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-32.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 105.65 | ||
| Fwd PE | 20.88 | ||
| P/S | 1.54 | ||
| P/FCF | 22.01 | ||
| P/OCF | 17.36 | ||
| P/B | 1.37 | ||
| P/tB | 7.69 | ||
| EV/EBITDA | 7.77 |
EPS(TTM)0.23
EY0.95%
EPS(NY)1.16
Fwd EY4.79%
FCF(TTM)1.1
FCFY4.54%
OCF(TTM)1.4
OCFY5.76%
SpS15.81
BVpS17.71
TBVpS3.16
PEG (NY)N/A
PEG (5Y)15.5
Graham Number9.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| ROCE | 6.02% | ||
| ROIC | 4% | ||
| ROICexc | 4.6% | ||
| ROICexgc | 27.98% | ||
| OM | 7.62% | ||
| PM (TTM) | 1.46% | ||
| GM | 46.95% | ||
| FCFM | 6.98% |
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ROICexc(3y)7.07%
ROICexc(5y)35.47%
ROICexgc(3y)44.03%
ROICexgc(5y)78.19%
ROCE(3y)7.73%
ROCE(5y)25.78%
ROICexgc growth 3Y-35.35%
ROICexgc growth 5Y49.79%
ROICexc growth 3Y-58%
ROICexc growth 5Y39.27%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 0.41 | ||
| Cap/Depr | 16.48% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.68% | ||
| Profit Quality | 479.21% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.25 | ||
| Altman-Z | 3.74 |
F-Score6
WACC7.06%
ROIC/WACC0.57
Cap/Depr(3y)26.09%
Cap/Depr(5y)27.29%
Cap/Sales(3y)2.36%
Cap/Sales(5y)1.86%
Profit Quality(3y)322.49%
Profit Quality(5y)228.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-63.15%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.09%
EBIT growth 3Y-42.09%
EBIT growth 5Y88.7%
EBIT Next Year18.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.22%
FCF growth 3Y-40.57%
FCF growth 5Y31.67%
OCF growth 1Y-50.55%
OCF growth 3Y-36.72%
OCF growth 5Y27.33%
EUROBIO-SCIENTIFIC / ALERS.PA FAQ
What is the ChartMill fundamental rating of EUROBIO-SCIENTIFIC (ALERS.PA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA.
Can you provide the valuation status for EUROBIO-SCIENTIFIC?
ChartMill assigns a valuation rating of 5 / 10 to EUROBIO-SCIENTIFIC (ALERS.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for EUROBIO-SCIENTIFIC?
EUROBIO-SCIENTIFIC (ALERS.PA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of EUROBIO-SCIENTIFIC (ALERS.PA) stock?
The Price/Earnings (PE) ratio for EUROBIO-SCIENTIFIC (ALERS.PA) is 105.65 and the Price/Book (PB) ratio is 1.37.